M&A Deal Summary |
|
---|---|
Date | 2017-11-29 |
Target | The Medicines Company - Infectious Disease Business |
Sector | Life Science |
Buyer(s) | Melinta Therapeutics |
Sellers(s) | The Medicines Company |
Deal Type | Divestiture |
Deal Value | 270M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
State (New Jersey) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2017) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-02-05 |
Melinta Therapeutics - Fusidic Acid
New Haven, Connecticut, United States Melinta Therapeutics, Inc. - Fusidic Acid is an antibiotic that is often used topically in creams and eyedrops but may also be given systemically as tablets or injections. |
Sell | - |
Category | Company |
---|---|
Founded | 1996 |
Sector | Life Science |
Employees | 62 |
Revenue | 6M USD (2018) |
The Medicines Company is a provider of solutions in acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The Medicines Company was formed in 1996 and is based in Parsippany, New Jersey. The Medicines was founded in 1996 and is based in Parsippany, New Jersey.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 2 of 2 |
Type (Divestiture) | 2 of 2 |
State (New Jersey) | 1 of 1 |
Country (United States) | 2 of 2 |
Year (2017) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-12-18 |
Medicines Company - Hemostasis Products
United States Medicines Company - Hemostasis Products are RECOTHROM Thrombin topical (Recombinant), PreveLeak, and RAPLIXA (fibrin sealant) products used for blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques. |
Sell | $175M |